MADRIGAL PHARMACEUTICALS, INC.: BAKER BROS. ADVISORS LP amends Schedule 13D stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Baker Bros. Advisors LP amended its Schedule 13D stake filing for Madrigal Pharmaceuticals, Inc., disclosing the change to the SEC under accession number 0001104659-26-124003. The amendment updates the investment firm's previously reported beneficial ownership position in the liver-disease drugmaker. Schedule 13D filings are required when an investor holds more than 5% of a company's shares and are closely watched for signals about activist or strategic intent. Investors will look to the revised filing for the exact share count, any change in percentage ownership, and the purpose of the transaction.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13D's report. It can get details wrong, so check the source.
Named in this story
BAKER BROS. ADVISORS LP, MADRIGAL PHARMACEUTICALS, INC.